UNICREDIT BANK/PUT/VERTEX PHARMACEUTICALS/450/0.1/18.09.24 | Real-time BOERSE MUENCHEN 20:40:44 05/07/2024 BST | ||
| 1.02 EUR | -8.93% |
|
| Current month | -9.73% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 05/07/24 | 1.02 | -8.93% |
| 04/07/24 | 1.12 | 0.00% |
| 03/07/24 | 1.12 | +6.67% |
| 02/07/24 | 1.05 | -7.08% |
| 01/07/24 | 1.13 | 0.00% |
Real-time BOERSE MUENCHEN
Last update July 05, 2024 at 08:40 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
UniCredit
|
| WKN | HD6JJS |
| ISIN | DE000HD6JJS8 |
| Date issued | 24/06/2024 |
| Strike | 450 $ |
| Maturity | 18/09/2024 (73 Days) |
| Parity | 10 : 1 |
| Emission price | 1.39 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.23 € |
|---|---|
| Lowest since issue | 0.93 € |
| Spread | 0.04 € |
| Spread % | 3.88% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
474.6
USD
Average target price
468.3
USD
Spread / Average Target
-1.33%
- Stock Market
- Warrants
- Warrant
